Introduction: Individuals with subjective cognitive decline (SCD) are at increased risk for clinical progression. We studied how combining different diagnostic tests can help to identify individuals who are likely to show clinical progression. Methods: We included 674 patients with SCD (46% female, 64 ± 9 years, Mini–Mental State Examination 28 ± 2) from three memory clinic cohorts. A multivariate model based on the Disease State Index classifier incorporated the available baseline tests to predict progression to MCI or dementia over time. We developed and internally validated the model in one cohort and externally validated it in the other cohorts. Results: After 2.9 ± 2.0 years, 151(22%) patients showed clinical progression. Overall perfo...
Background: The PredictAD tool integrates heterogeneous data such as imaging, cerebrospinal fluid bi...
We evaluated the performance of the Disease State Index (DSI) method when predicting progression to ...
Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and ...
Introduction: Individuals with subjective cognitive decline (SCD) are at increased risk for clinical...
BACKGROUND: In clinical practice, it is often difficult to predict which patients with cognitive com...
Background: In clinical practice, it is often difficult to predict which patients with cognitive com...
Abstract Background: In clinical practice, it is often difficult to predict which patients with cog...
Abstract Background In clinical practice, it is often difficult to predict which patients with cogni...
INTRODUCTION: We established a method for diagnostic harmonization across multiple studies of precli...
Background: The characterizing symptom of Alzheimer disease (AD) is cognitive deterioration. While m...
Alzheimer’s disease (AD), the most common form of dementia, is a slowly progressing neurodegenerativ...
BackgroundWe previously operationally-defined subtle cognitive decline (SCD) in preclinical Alzheime...
International audienceSubjective cognitive decline (SCD) is a high-risk yet less understood status b...
<div><p>Background</p><p>Mild cognitive impairment is often a precursor to dementia due to Alzheimer...
International audienceWe performed a systematic review of studies focusing on the automatic predicti...
Background: The PredictAD tool integrates heterogeneous data such as imaging, cerebrospinal fluid bi...
We evaluated the performance of the Disease State Index (DSI) method when predicting progression to ...
Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and ...
Introduction: Individuals with subjective cognitive decline (SCD) are at increased risk for clinical...
BACKGROUND: In clinical practice, it is often difficult to predict which patients with cognitive com...
Background: In clinical practice, it is often difficult to predict which patients with cognitive com...
Abstract Background: In clinical practice, it is often difficult to predict which patients with cog...
Abstract Background In clinical practice, it is often difficult to predict which patients with cogni...
INTRODUCTION: We established a method for diagnostic harmonization across multiple studies of precli...
Background: The characterizing symptom of Alzheimer disease (AD) is cognitive deterioration. While m...
Alzheimer’s disease (AD), the most common form of dementia, is a slowly progressing neurodegenerativ...
BackgroundWe previously operationally-defined subtle cognitive decline (SCD) in preclinical Alzheime...
International audienceSubjective cognitive decline (SCD) is a high-risk yet less understood status b...
<div><p>Background</p><p>Mild cognitive impairment is often a precursor to dementia due to Alzheimer...
International audienceWe performed a systematic review of studies focusing on the automatic predicti...
Background: The PredictAD tool integrates heterogeneous data such as imaging, cerebrospinal fluid bi...
We evaluated the performance of the Disease State Index (DSI) method when predicting progression to ...
Several neuropsychological tests and biomarkers of Alzheimer's disease (AD) have been validated and ...